Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process─Part 3
Organic Process Research & Development · 18.11.2026
DOI: 10.1021/acs.oprd.6c00298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 18.11.2026. Verfasst von John S. Carey und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
In campaign 1, 124.3 kg of 2-methyl-5-(2H-1,2,3-triazol-2-yl)pyridine N-oxide (8) was prepared in 2 stages from 5-bromo-2-methylpyridine. The first stage was a regioselective copper-catalyzed Ullmann reaction using 1H-1,2,3-triazole. The second stage was an oxidation with peracetic acid to form the corresponding pyridine N-oxide. In campaign 2, 223.8 kg of 2-methyl-5-(2H-1,2,3-triazol-2-yl)pyridine N-oxide (8) was prepared. An alternative palladium-catalyzed Buchwald−Hartwig approach using Me4tBuXPhos as a ligand was developed but not scaled up. 2-Methyl-5-(2H-1,2,3-triazol-2-yl)pyridine N-oxide (8) is a key intermediate in the synthesis of the orexin 1 receptor antagonist C4X3256.
Zitieren
APA
Carey, J. S., Churchill, J. C., & Leong, P. (2026). Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process─Part 3. Organic Process Research & Development. https://doi.org/10.1021/acs.oprd.6c00298
Vancouver
Carey JS, Churchill JC, Leong P. Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process─Part 3. Organic Process Research & Development. 2026. doi:10.1021/acs.oprd.6c00298
BibTeX
@article{Carey2026,
author = {Carey, John S. and Churchill, Jonathan C. and Leong, Paul},
title = {Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process─Part 3},
journal = {Organic Process Research & Development},
year = {2026},
doi = {10.1021/acs.oprd.6c00298}
}
EUVIMED